Pancreatic Cancer in Veterans: Expert Insights for Optimal Treatment

In this CME/CE-certified series of 1-hour workshops, CCO’s expert faculty provide perspective on best practices in the treatment of pancreatic cancer within the VHA system.

Agenda

Welcome and Program Overview

Overview of Pancreatic Cancer

Interactive Case-Based Discussions

Optimal treatment approach for newly diagnosed advanced pancreatic cancer

  • Current data and guideline recommendations (VHA, NCCN)
  • Best practice strategies to identify patients most likely to benefit from gemcitabine, albumin-bound paclitaxel plus gemcitabine, erlotinib plus gemcitabine, or FOLFIRINOX
  • Individualizing treatment

Selecting treatment for patients with advanced pancreatic cancer who progress after initial therapy

  • Monitoring response to therapy
  • Current data and guideline recommendations (VHA, NCCN) for progression after albumin-bound paclitaxel plus gemcitabine or FOLFIRINOX
  • Use of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin after progression on gemcitabine
  • Radiotherapy
  • Supportive and palliative care

Ongoing surveillance and management strategies for disease-related and treatment-related adverse events

Future Directions in Advanced Pancreatic Adenocarcinoma

  • Disease heterogeneity
  • Molecular characterization and potential drug targets
  • Novel therapies: immunotherapy, combination chemotherapy, and JAK, PARP, and MEK inhibitors

Closing Remarks

Events

Date / Time
Event Details
3/29/2017
8:00 AM

Pancreatic Cancer

Fayetteville, NC
Fayetteville VA Healthcare Center Details

Faculty

Tanios Bekaii-Saab, MD

Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Professor of Medicine
Mayo Clinic
Scottsdale, Arizona

Al B. Benson III, MD, FACP

Professor of Medicine
Department of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine 
Associate Director for Clinical Investigations
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Thomas Cartwright, MD

Co-Chairman, US Oncology GI Research
US Oncology/Florida Cancer Affiliates
Ocala, Florida

Steven J. Cohen, MD

Associate Professor
Department of Hematology/Oncology
Chief, Gastrointestinal Medical Oncology
American Oncologic Hospital d/b/a The Hospital of Fox Chase Cancer Center
Medical Director
Hematology/Oncology
Fox Chase Cancer Center Partners
Philadelphia, Pennsylvania

Herbert Hurwitz, MD

Professor
Division of Medical Oncology
Duke University Medical Center
Attending Physician
Duke Cancer Institute
Durham, North Carolina

Andrew Ko, MD

Professor, Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Fa Chyi Lee, MD

Professor, Department of Internal Medicine
Chief, Section of Gastrointestinal Oncology
University of New Mexico
Albuquerque, New Mexico

Kian H. Lim, MD, PhD

Assistant Professor
Division of Oncology
Department of Medicine
Washington University School of Medicine
St Louis, Missouri

Michael J. Pishvaian, MD, PhD

Assistant Professor
Department of Medical Oncology
Phase I Program Director
Department of Hematology/Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Colin Weekes, MD, PhD

Associate Professor of Medicine
Director, Pancreas Medical Oncology Program
Division of Medical Oncology
University of Colorado, Denver
Aurora, Colorado

CME

Program Overview
This CME/CE-certified series of live meetings features expert discussion of the treatment of advanced pancreatic cancer for clinicians practicing in the Department of Veterans Affairs healthcare system.

Goal Statement
The goal of this activity is to improve participants’ competence in selecting and applying optimal therapeutic strategies for veterans with newly diagnosed or relapsed/refractory advanced pancreatic cancer.

Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals working within the VHA system who care for patients with advanced pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the most recent clinical findings and best practices to select optimal therapies for patients with newly diagnosed advanced pancreatic cancer
  • Integrate key recent clinical findings and best practices to monitor response and optimize therapy for patients with advanced pancreatic cancer that has progressed after initial therapy
  • Choose best strategies to manage disease-related and treatment-related symptoms in patients with advanced pancreatic cancer

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Continuing Education
ACPE logo

Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-16-331-L01-P)

Type of Activity
Knowledge

Upon receipt of the completed activity evaluation form, you will receive an email from the Postgraduate Institute for Medicine within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.